Mission Statement
“Lexander Limited is dedicated to producing innovative, top quality biotech, healthcare and pharma products, using leading edge technology to guarantee customer satisfaction, every time.”
Markets: Biotechnology
Company Name: Lexander Limited
Period: 2001 - 2008
New Production Facilities
Investment in new production facilities was required to meet the demands of emerging markets in water treatment and to diversify and expand the product range.
Commercial Opportunity
A significant commercial opportunity was created with the introduction of legislation to reduce the volume of organic material in wastewaters and enable discharge into the local waterways, to meet the discharge consents regulated by the Environment Agency.
Market
New markets in commercial biotechnology for water treatment applications quickly emerged for the treatment of natural water sites (industrial ponds, lagoons and lakes) where large amounts of water were required for manufacturing processes.
The product range was further extended to address other bioaugmentation and bioremediation applications.
In addition, a range of probiotics for the veterinary and farming sectors was developed.
Lexander Limited
Lexander Limited was formed in 2001, to produce a range of natural bioremediation products for a wide range of applications in both industrial and leisure environments and to develop new technologies to position the company at the forefront of the bioremediation industry.
SMART Objectives
Development of a new production facility to be completed by the end of 2005 with the capacity to produce some 120,000 units per week
1.
Continuous income from expansion of key customer base bringing Lexander Limited’s current plant to maximum capacity
2.
Develop QMS and achieve industry standards necessary to move into the higher value markets
3.
Establish balanced and trained workforce capable of running the current facility as a self-contained unit
4.
Diversification into high value products in the healthcare and pharmaceutical industries
5.
Management
Additional responsibility for each objective was assigned to specific members of the management team and weekly meetings held to manage progress.
Funding
Revenue from EcoPure, personal funds, numerous grants and business awards contributed to the funding package to complete the next stage of business growth.
KPIs
The following key performance indicator categories were used to guide the business:
1. Plant output and efficiency
2. Sales performance
3. QMS implementation and accreditation
Success
The new production facility was completed by the end of 2005 with the capacity to produce some 120,000 units per week.
This facility extended to some 5,000 square feet and included a fully automated manufacturing, filling and capping line, with front/back labelling, capable of meeting Class 100 quality standards enabling production of up to oral-grade pharmaceuticals.
The unit also accommodated a laboratory, cleanroom, incubation facilities, warehouse space and an office suite.